VG 18563

Drug Profile

VG 18563

Alternative Names: VG-18563

Latest Information Update: 12 May 2011

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Antianaemics; Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cancer; Haematological disorders

Most Recent Events

  • 12 May 2011 Discontinued - Preclinical for Haematological disorders in USA (PO)
  • 12 May 2011 Discontinued - Preclinical for Cancer in USA (PO)
  • 22 Jun 2001 No-Development-Reported for Haematological disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top